Fig. 7: Loss of 5-hmC contributes to the resistance against oxaliplatin and 5-FU. | Cell Death & Disease

Fig. 7: Loss of 5-hmC contributes to the resistance against oxaliplatin and 5-FU.

From: Loss of 5-hydroxymethylcytosine induces chemotherapy resistance in hepatocellular carcinoma via the 5-hmC/PCAF/AKT axis

Fig. 7

A, B Kaplan–Meier estimates overall survival and cumulative recurrence rate of advanced recurrent HCC patients after TACE combined oxaliplatin and 5-FU treatment with different levels of 5-mC; Log-rank test, *P < 0.05; **P < 0.01. C, D 5-hmC staining in post-transplantation, preventive chemotherapy-treated HCC patients with or without recurrence; Wilcoxon rank-sum test, ***P < 0.01. All data are presented as mean ± SD; n = 3. **P < 0.001; ***P < 0.01.

Back to article page